Piper Sandler began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ – Free Report) in a research note released on Wednesday, MarketBeat.com reports. The firm issued an overweight rating and a $28.00 target price on the stock.
LENZ Therapeutics Stock Up 30.3 %
Shares of LENZ Therapeutics stock opened at $21.81 on Wednesday. LENZ Therapeutics has a twelve month low of $14.07 and a twelve month high of $29.82. The stock has a market capitalization of $181.46 million, a P/E ratio of -1.40 and a beta of 0.20.
Insider Activity at LENZ Therapeutics
In other news, Director Ra Capital Management, L.P. acquired 998,009 shares of the stock in a transaction that occurred on Thursday, March 21st. The shares were bought at an average cost of $15.03 per share, for a total transaction of $15,000,075.27. Following the acquisition, the director now owns 3,319,339 shares in the company, valued at approximately $49,889,665.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 38.40% of the stock is owned by company insiders.
LENZ Therapeutics Company Profile
Graphite Bio Inc is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc is based in SOUTH SAN FRANCISCO, Calif.
Recommended Stories
- Five stocks we like better than LENZ Therapeutics
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Best Bear Market Funds: Top 3 Investment Options to Consider
- 3 Stocks to Consider Buying in October
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Conference Calls and Individual Investors
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
